MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

Ocular Therapeutix Inc

Open

SectorGezondheidszorg

7.8 -0.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.61

Max

7.97

Belangrijke statistieken

By Trading Economics

Inkomsten

-12M

-48M

Verkoop

1.7M

17M

EPS

-0.29

Winstmarge

-283.269

Werknemers

274

EBITDA

-12M

-44M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+124.05% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

279M

1.2B

Vorige openingsprijs

8.69

Vorige sluitingsprijs

7.8

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Ocular Therapeutix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr 2025, 23:51 UTC

Marktinformatie

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr 2025, 23:37 UTC

Top Nieuws

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr 2025, 23:36 UTC

Top Nieuws

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr 2025, 23:13 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr 2025, 23:09 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr 2025, 22:51 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 22:48 UTC

Top Nieuws

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr 2025, 22:47 UTC

Marktinformatie

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr 2025, 22:38 UTC

Marktinformatie
Winsten

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr 2025, 22:24 UTC

Marktinformatie
Winsten

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr 2025, 22:23 UTC

Winsten

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr 2025, 22:09 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr 2025, 22:00 UTC

Marktinformatie
Winsten

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr 2025, 21:39 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr 2025, 21:23 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr 2025, 21:04 UTC

Winsten

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr 2025, 21:02 UTC

Winsten

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Vergelijking

Prijswijziging

Ocular Therapeutix Inc Prognose

Koersdoel

By TipRanks

124.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 17.7 USD  124.05%

Hoogste 22 USD

Laagste 14 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocular Therapeutix Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technische score

By Trading Central

7.11 / 8.23Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.